ID   TBL.Cl2
AC   CVCL_D7CG
SY   TBL CL2; TBLC2
RX   PubMed=4660932;
RX   PubMed=4932229;
RX   PubMed=11378348;
CC   Transformant: ChEBI; CHEBI_34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Breed/subspecies: C57BL/6J.
DI   NCIt; C21603; Mouse sarcoma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
SX   Male
CA   Cancer cell line
DT   Created: 10-09-24; Last updated: 19-12-24; Version: 2
//
RX   PubMed=4660932; DOI=10.1002/ijc.2910090302;
RA   Belehradek J. Jr., Barski G., Thonier M.;
RT   "Evolution of cell-mediated antitumor immunity in mice bearing a
RT   syngeneic chemically induced tumor. Influence of tumor growth,
RT   surgical removal and treatment with irradiated tumor cells.";
RL   Int. J. Cancer 9:461-469(1972).
//
RX   PubMed=4932229; DOI=10.1002/ijc.2910070222;
RA   Barbieri D., Belehradek J. Jr., Barski G.;
RT   "Decrease in tumor-producing capacity of mouse cell lines following
RT   infection with mouse leukemia viruses.";
RL   Int. J. Cancer 7:364-371(1971).
//
RX   PubMed=11378348; DOI=10.1016/s0959-8049(01)00091-0;
RA   Cemazar M., Miklavcic D., Mir L.M., Belehradek J. Jr., Bonnay M.,
RA   Fourcault D., Sersa G.;
RT   "Electrochemotherapy of tumours resistant to cisplatin: a study in a
RT   murine tumour model.";
RL   Eur. J. Cancer 37:1166-1172(2001).
//